37. (New) A pharmaceutical composition comprising the hSP of claim 28 together with a pharmaceutically acceptable carrier or excipient.

38. (New) A method for the treatment of gastrointestinal disorders, comprising administering the pharmaceutical composition of claim 37.

35
39. (New) The method of claim 36, wherein the host cell is a Saccharomyces cerevisiae or Aspergillus oryzae.

REMARKS

This amendment is submitted to cancel claims 1-27 and present new claims 28-39. No new matter added, and entry of the amendment is respectfully requested.

Respectfully submitted,

Date: 17 March 2000

Valeta A. Gregg, Reg. No. 35,126 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123